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Mutations in the parkin gene are the most common cause of early-onset Parkinson’s disease (PD). Parkin, an E3 ubiquitin ligase, is
involved in respiratory chain function,mitophagy, andmitochondrial dynamics. Human cellularmodels with parkin nullmutations
are particularly valuable for investigating the mitochondrial functions of parkin. However, published results reporting on patient-
derived parkin-mutant fibroblasts have been inconsistent.This study aimed to functionally compare parkin-mutant fibroblasts from
PD patients with wild-type control fibroblasts using a variety of assays to gain a better understanding of the role of mitochondrial
dysfunction in PD. To this end, dermal fibroblasts were obtained from three PD patients with homozygous whole exon deletions
in parkin and three unaffected controls. Assays of mitochondrial respiration, mitochondrial network integrity, mitochondrial
membrane potential, and cell growth were performed as informative markers of mitochondrial function. Surprisingly, it was found
that mitochondrial respiratory rates were markedly higher in the parkin-mutant fibroblasts compared to control fibroblasts (p
= 0.0093), while exhibiting more fragmented mitochondrial networks (𝑝 = 0.0304). Moreover, cell growth of the parkin-mutant
fibroblasts was significantly higher than that of controls (𝑝 = 0.0001).These unanticipated findings are suggestive of a compensatory
mechanism to preserve mitochondrial function and quality control in the absence of parkin in fibroblasts, which warrants further
investigation.
1. Introduction
Parkinson’s disease (PD) is a progressive and debilitating
neurodegenerative disorder, characterized by a distinctmotor
phenotype and the selective loss of dopaminergic neurons in
the substantia nigra. While the etiology of PD is not fully
understood, it is thought to involve a combination of different
genetic, cellular, and environmental factors that indepen-
dently or concurrently contribute to neurodegeneration. To
date, several PD-causing genes have been identified, and
investigations of their function have provided novel insights
into the pathobiology of this disease [1].
Recently, particular attention has been drawn to parkin,
mutations in which are the most common genetic cause
of early-onset PD. Over 200 different pathogenic parkin
mutations have been reported to date, includingmissense and
nonsense mutations, small insertions/deletions (indels), and
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large whole exon deletions and duplications, across various
ethnic groups [2, 3]. Parkin is a RING-between-RING- (RBR-
) type E3 ligase that ubiquitinates protein substrates and
targets such substrates for degradation via the ubiquitin
proteasome system (UPS). Therefore, the loss of functional
parkin may result in the deleterious dysregulation of its
substrates and may lead to cellular dysfunction and neuronal
cell death [4].
Parkin’s enzymatic activity has also been implicated in
the maintenance of mitochondrial health, and mitochon-
drial dysfunction is commonly reported in animal mod-
els of parkin deficiency [5]. For example, parkin-knockout
Drosophila demonstrate prominent mitochondrial abnor-
malities, muscle degeneration, and dopaminergic degener-
ation [6–8]. While parkin-knockout mice exhibit milder
neurological deficits, they consistently show mitochondrial
impairment and oxidative damage [9, 10]. Recent studies have
elegantly demonstrated the pivotal role of parkin in promot-
ing the sequestration and autophagic degradation of dam-
agedmitochondria (mitophagy) [11–14]. Uponmitochondrial
depolarization, parkin is recruited to the outer mitochon-
drial membrane (OMM) through direct phosphorylation by
PINK1, where it ubiquitinates several OMM proteins [15–
18]. This widespread ubiquitination of OMM proteins results
in the recruitment of the autophagy machinery and the
autophagic clearance of damaged mitochondria, promoting
cell survival [19].
In addition to its important role in mitophagy, parkin
is also involved in the regulation of mitochondrial fission
and fusion, continuous processes that orchestrate a dynamic
cellular network of mitochondria. These processes fine-
tune the mitochondrial network in response to changes in
the metabolic environment, in order to maintain favorable
mitochondrial function duringmetabolic perturbations [20].
Moreover, parkin promotes mitochondrial biogenesis via its
UPS-dependent regulation of the PARIS-PGC-1𝛼 pathway
[21]. Interestingly, parkin also directs the localized translation
of mitochondrial respiratory chain component mRNA at the
OMM [22]. Hence, it is evident that parkin plays important
roles in the promotion and coordination of various aspects
of mitochondrial health, including degradation of damaged
mitochondria, mitochondrial dynamics, and mitochondrial
biogenesis. It is hypothesized that dysregulation of the careful
balance between these processes may significantly compro-
mise mitochondrial health [23]. However, the exact role of
mitochondrial function in the pathogenesis of PD remains
largely unclear.
Notably valuable in the investigation of PD-associated
mitochondrial dysfunction are patient-derived primary cell
models of PD [24]. Parkin-mutant dermal fibroblasts in
particular are a useful and easily accessible tool to study
mitochondrial phenotypes in an ex vivo setting. However,
previous studies of fibroblasts from patients with parkin
mutations have been inconsistent [25–29]. We have previ-
ously reported subtle mitochondrial abnormalities in dermal
fibroblasts obtained from three South African early-onset
PD patients carrying homozygous loss-of-function parkin
mutations [28]. The present study serves to follow-up our
previous report with a more comprehensive analysis of
mitochondrial respiration, and with the inclusion of three
age- and gender-matched control individuals.
2. Materials and Methods
2.1. Study Participants and Tissue Culture. This study gained
ethical approval from the Health Research Ethics Committee
of Stellenbosch University, Cape Town, South Africa (Pro-
tocol number 2002/C059). Written informed consent was
obtained from all participants.
Dermal fibroblasts were previously obtained from three
South African PD patients with homozygous parkin muta-
tions, namely, patient 1 (P1) and a pair of affected siblings
patients 2 and 3 (P2 and P3) [28]. All three patients under-
went a standardized examination by a movement disorder
specialist (JC) and met the UK Parkinson’s Disease Society
Brain Bank diagnostic criteria for PD diagnosis [30]. P1
presented with mild dyskinesia, resting tremor, and dystonia
of the left leg and responded well to levodopa therapy. Both
P2 and sibling P3 presented with typical PD features as well
as dystonia, while P3 exhibited greater disease severity. Each
patient’s mutation status (P1, homozygous parkin exon 3-4
deletion; P2 and P3, homozygous parkin exon 4 deletion)
was confirmed by means of multiplex ligation-dependent
probe amplification (MLPA) analysis and cDNA sequencing,
as previously reported [31, 32].
Three age- and gender-matched control individuals were
also used, namely, Ct1, Ct2, and Ct3. The three controls had
no history of neurological disease and were confirmed to be
wild-type with regard to the parkin gene by means of cDNA
sequencing. Relevant genotypic and phenotypic details of
the three PD patients and three controls are summarized in
Table 1.
Dermal fibroblasts were obtained fromP1, P2, P3, and Ct1
by means of skin punch biopsies taken from the inner upper
arm. Ct2 and Ct3 fibroblast cell lines were purchased from
Sciencell Laboratories (USA) and were selected to be age-
and gender-matched to patient fibroblasts. Fibroblasts were
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM,
Lonza, Switzerland) with 4.5 g/L glucose supplemented with
10% (v/v) fetal bovine serum, 1% (v/v) L-glutamine, and 1%
(v/v) penicillin/streptomycin, in a 5% CO
2
humidified incu-
bator at 37∘C. All experiments were performed on fibroblasts
with comparable passage numbers, ranging from 6 to 12, in
order to avoid possible effects of cellular senescence.
2.2. Mitochondrial Respiration Analysis. Measurements of
mitochondrial respiration are strong indicators of the func-
tional bioenergetic capacity of mitochondria, and of overall
cellular health. The Seahorse Extracellular Flux Analyzer
uses a plate-based approach and fluorescence detectors to
accurately and simultaneously measure cellular oxygen con-
sumption rates (OCR) of multiple samples in real time [33].
Moreover, the Seahorse Analyzer allows for the sequential
addition of pharmacological reagents to probe the function
of individual components of the mitochondrial respiratory
chain in a single experiment.This can be expressed as various
informative parameters of mitochondrial function [34].
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Table 1: Genotypic and demographic characteristics of the six dermal fibroblast donors used in this study.
Identifier Lab ID Parkinmutation Gender AAO (years) AAR∗ (years) PD duration(years)
PD patients
P1 53.44 Deletion exon 3-4 hom Female 27 39 12
P2 P2 Deletion exon 4 hom Female 27 54 27
P3 P3 Deletion exon 4 hom Female 27 52 25
Controls
Ct1 WT2 n/a Female n/a 62 n/a
Ct2 WT3 n/a Female n/a 56 n/a
Ct3 WT4 n/a Female n/a 44 n/a
∗The age of the donor at the time of skin punch biopsy. AAO, age at onset; AAR, age at recruitment; hom, homozygous; n/a, not applicable; PD, Parkinson’s
disease.
Mitochondrial respiration assays were performed using
a Seahorse XF96 Cell Mito Stress Test Kit (Seahorse Bio-
sciences, USA), in accordance with manufacturer’s instruc-
tions. Briefly, fibroblasts were seeded at an optimized density
of 22 000 cells per well in a 96-well Seahorse cell culture plate
and incubated overnight. Each fibroblasts cell line was seeded
in eight replicate wells (𝑁 = 8). After 24 h, the Seahorse
XFe96 Extracellular Flux Analyzer (Seahorse Biosciences,
USA) along with XFe Wave software (Seahorse Biosciences,
USA) was used to measure the OCR of each well. A period of
1 h before the measurements was initiated, the culture media
in each well was replaced with 175 𝜇L of Seahorse assaymedia
supplemented with 1mM pyruvate, and the plate was further
incubated for 1 h at 37∘C without CO
2
. Thereafter, successive
OCR measurements was performed for each well, consisting
of three basal OCRmeasurements, three OCRmeasurements
following the automated injection of 1𝜇M oligomycin, three
OCRmeasurements following the injection of 1 𝜇M carbonyl
cyanide p-trifluoromethoxyphenyl hydrazone (FCCP), and
finally three OCRmeasurements following the dual injection
of 1 𝜇M rotenone and 1 𝜇M antimycin A. Subsequently, rela-
tiveDNAcontent in eachwell of the platewasmeasured using
a CyQUANT cell proliferation assay kit (Life Technologies,
USA).
The Seahorse assays were analyzed using XFe Wave
software, according to manufacturer’s instructions. All OCR
measurements were normalized to cell number and used to
calculate various mitochondrial parameters, including basal
mitochondrial OCR, OCR due to the proton leak across the
inner mitochondrial membrane, OCR due to ATP synthesis,
ATP coupling efficiency, and maximum OCR and spare
respiratory capacity, following established methods [34]. The
minimumOCR after rotenone and antimycinA injectionwas
interpreted as the OCR due to nonmitochondrial respiration,
and this rate was subtracted from all other measurements in
order to isolate mitochondrial OCR.
2.3. Mitochondrial Network Analysis. Mitochondrial mor-
phology of fibroblast cells was assessed by means of live-
cell fluorescence microscopy, where staining with the Mito-
tracker Red dye was used to visualize the mitochondrial
network. Cells were seeded at a density of 3000 cells per well
in aNuncLab-Tek 8-well chamber slide (ThermoScientific,
USA), which was then incubated overnight. Subsequently,
cells were stained with a 100 nM solution of Mitotracker Red
CMXRos (Life Technologies, USA) and imaged inside a live-
cell environmental chamber of an Olympus IX-81 motor-
ized inverted fluorescence microscope (Olympus Biosystems
GmbH, Japan) equipped with a F-view-II cooled CCD
camera (Soft Imaging Systems, Germany). Fluorescence was
excited through a 572 nm excitation filter, and fluorescence
emission collected at 599 nm using a UBG triple-bypass
emission filter cube and an Olympus Plan AP N 60X/1.42
oil-immersion objective. All images were acquired as Z-
stacks, with 7–12 image frames per stack and increments of
0.26–0.3 𝜇m between frames, using Cell∧R imaging software
(Olympus Biosystems GmbH, Tokyo, Japan).
Following image acquisition, micrographs were decon-
voluted in order to remove out-of-focus fluorescent signal.
Cells were individually analyzed using ImageJ Software ver-
sion 1.47 (http://imagej.nih.gov/ij/) with an average of 40
cells analyzed per sample. Raw images were binarized and
optimized by manual contrast adjustment. The individual
morphological characteristics of the mitochondria within a
given cell, such as area, perimeter, and major and minor
axes, were measured and used to calculate aspect ratio (ratio
between the major and minor axes of the ellipse equivalent
to the mitochondrion) and form factor (perimeter2/(4𝜋 ×
area)) [25]. Aspect ratio is consistent with mitochondrial
length, whereas form factor is a quantification of the degree
of branching of the mitochondrial network.
It should be noted that while the mitochondrial respira-
tory andnetwork analyseswas performedon all three patient-
derived fibroblast cell lines P1, P2, and P3, due to microbial
contamination of the stocks of P1’s fibroblasts these cells had
to be discarded; therefore only P2 and P3 were available for
the assays of Δ𝜓
𝑚
and cell growth.
2.4. Mitochondrial Membrane Potential Analysis. In the
present study, mitochondrial membrane potential (Δ𝜓
𝑚
) was
assessed with the tetraethyl benzimidazolyl carbocyanine
iodide (JC-1) cationic dye and flow cytometric analysis. JC-1
exhibits potential-dependent accumulation in mitochondria,
resulting in a fluorescence emission shift from525 nm (green)
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to 590 nm (red). Therefore, loss of Δ𝜓
𝑚
is detectable by the
decrease in the red : green fluorescence emission ratio [35].
Cultured fibroblasts were incubated with 0.5 𝜇g/mL JC-1
(Life Technologies, USA) in the dark for 1 h.The stained cells
were collected, rinsed, and resuspended in prewarmed sterile
phosphate-buffered saline (PBS). JC-1 dye equilibration was
allowed for 10min at room temperature, after which the
stained cell suspensions were immediately analyzed on a
BD FACSCalibur flow cytometer (Becton Dickinson, USA)
using BDCellQuest PRO software (Becton Dickinson, USA).
The JC-1 fluorophore was excited with a 488 nm argon-ion
laser after which red and green emission were separately
detected in the FL1 and FL2 channels, respectively, using
standard PMT detectors. Debris and aggregates were gated
out by establishing a population of interest based on forward
scatter/side scatter (FSC/SSC) properties. Compensation
between FL1 and FL2 was carefully adjusted in reference to
a CCCP-treated positive control sample, according to the
manufacturer’s instructions. A total of 10 000 events were
collected per sample in each of three separate experiments
(𝑁 = 3).
2.5. Cell Growth Assays. Cell growth rate is considered to be
one of the most sensitive and reliable indicators of overall
cellular health [36].Thepresent study investigated cell growth
of fibroblasts bymeans of CyQUANT assays, whichmeasures
cellular DNA content via fluorescent dye binding. As DNA
content is tightly regulated, CyQUANT assays can be used
as accurate measurements of cell number. Fibroblasts were
seeded in quadruplicate into a 96-well plate at a density of
5000 cells perwell and left to adhere overnight. Culturemedia
was then replaced and supplemented with either 10 𝜇M car-
bonyl cyanide m-chlorophenylhydrazone (CCCP, to induce
cellular stress) or 0.1% (v/v) ethanol (vehicle control), and
the plate incubated further for 24 h. Cell growth assays
were performed using a CyQUANT NF Cell Proliferation
Kit (Life Technologies, USA), according to manufacturer’s
instructions. Briefly, adherent cells in the 96-well plate were
gently rinsed once with prewarmed sterile PBS and a volume
of 100 𝜇L of 1x dye binding solution was added to each
well. The plate was then incubated in the dark for 1 h.
Subsequent fluorescence intensity wasmeasured in a Synergy
HT luminometer (BioTek, USA) with excitation at 480 nm
and emission detection at 530 nm.
2.6. Statistical Analysis. Linear mixed-effects modeling was
used to compare grouped patient-derived and control fibrob-
lasts, with groups as fixed effects.The freely available program
R, a language and environment for graphics and statisti-
cal computing (https://www.r-project.org/), and R packages
nlme and effects were used [37]. Adjustments were made for
the effect that the different observations on a specific cell line
will be correlated. Separate experimental runs were modeled
as random effects. Where appropriate, a 22 factorial design
was used to model effects of pharmacological treatment on
outcomes. Outcome distributions were graphically depicted
as boxplots with indicated medians. Where appropriate,
notched boxplots were used to indicate the 95% confidence
intervals of the medians. For analysis of mitochondrial
network morphology, all outcome distributions were trans-
formed (taking the natural logarithm) in order to approach
normality, as the untransformed distributions of form factor
and aspect ratio were positively skewed. Results were not
adjusted for multiple testing because it has been suggested
that corrections, such as Bonferroni, are too conservative
when several associations are tested in the same group of
individuals [38]. All 𝑝 values were derived from the results of
the specific models, where 𝑝 values of < 0.05 were considered
to be of nominal statistical significance.
3. Results
3.1. Mitochondrial Respiratory Rates Are Elevated in Parkin-
Mutant Fibroblasts. In order to compare the bioenergetic
status of the three parkin-mutant and three wild-type control
fibroblasts, mitochondrial respiration analyses were per-
formed. All OCR readings were normalized to cell number.
The overall respiratory responses of all patient-derived and
control fibroblasts are illustrated in Figure 1(a), from which
several important respiratory parameters can be assessed
(Figure 1(b)).
A comparison of these parameters in grouped parkin-
mutant and wild-type control fibroblasts is provided in
Figure 2. Patient-derived fibroblasts had a markedly higher
mitochondrial respiration than control fibroblasts under
basal conditions (𝑝 = 0.0093; Figure 2(a)). This mito-
chondrial respiration is composed of two components: the
oxygen consumption devoted to ATP synthesis and the
oxygen consumption due to the natural proton leak across
the inner mitochondrial membrane. The addition of the
ATP synthase inhibitor oligomycin allowed for these con-
tributory components to be isolated. While parkin-mutant
fibroblasts demonstrated higher proton leak (𝑝 = 0.0375;
Figure 2(b)), the elevation in ATP-linked respiration was
more pronounced in these cells (𝑝 = 0.0060; Figure 2(c)).
A comparison of the ATP-coupling efficiency demonstrated
similar coupling efficiencies in parkin-mutant and control
cells (𝑝 = 0.5541; Figure 2(d)), suggesting that the lack of
parkin did not significantly impair respiratory efficiency in
the patient fibroblasts.
The addition of the accelerator FCCP allowed for an
estimation of the maximum, uncontrolled OCR. FCCP is an
ionophore which directly transports protons across the inner
mitochondrial membrane instead of via the ATP synthase
proton channel. Hence, addition of FCCP collapses Δ𝜓
𝑚
,
leading to a rapid consumption of oxygen without the gen-
eration of ATP. The maximal respiratory rate is determined
by several factors, including the functional capacity of the
electron transport chain. It was found that the patient-
derived cells had a markedly higher maximum respiratory
rate than control fibroblasts (𝑝 = 0.0081; Figure 2(e)),
whereas spare respiratory capacity was comparable between
these two groups (𝑝 = 0.1145; Figure 2(f)).
3.2. Parkin-Mutant Fibroblasts Demonstrate More Fragment-
ed Mitochondrial Networks. As parkin is involved in the
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Figure 1: Respiratory flux profiles of patient-derived and control
fibroblasts, as determined by a Seahorse Extracellular Flux Ana-
lyzer with twelve consecutive measurements of oxygen consump-
tion rate (OCR). Addition of ATP synthase inhibitor oligomycin,
electron transport chain uncoupler FCCP and complex I and
III inhibitors rotenone and antimycin A are indicated. (a) Res-
piratory flux profiles of patient-derived and control fibroblasts.
Results are expressed as mean ± SEM. (b) Illutrative respira-
tory flux profile indicating various parameters of respiratory con-
trol. These include: OCR due to non-mitochondrial respiration
(rotenone/antimycin A response); basal mitochondrial OCR (basal
measurement minus rotenone/antimycin A response); ATP-linked
OCR (basal measurement minus oligomycin response); OCR due
to proton leak (oligomycin response minus rotenone/antimycin
A response); ATP coupling efficiency (basal mitochondrial OCR
divided by ATP-linked OCR); maximum OCR (FCCP response
minus rotenone/antimycin A response) and spare respiratory capac-
ity (maximum OCR divided by basal mitochondrial OCR). AU,
arbitrary units; Ct, control; OCR, oxygen consumption rate; P,
patient; SEM, standard error of the mean.
regulation of mitochondrial dynamics, mitochondrial mor-
phologywas assessed in all parkin-mutant and control fibrob-
lasts by means of live-cell microscopy and image analysis.
Approximately 40 cells were analyzed from each fibroblast
cell line, and representative images of parkin-mutant and
control fibroblasts are shown in Figure 3(a). Each image was
assessed with regard to form factor (degree of mitochon-
drial branching) and aspect ratio (degree of mitochondrial
elongation). The form factor of patient-derived fibroblasts
was significantly lower than that of control cells (𝑝 =
0.0304; Figure 3(b)), which is consistent with a more frag-
mented mitochondrial network. No significant differences
were observed between the aspect ratios of patient-derived
and control fibroblasts (𝑝 = 0.1638; Figure 3(c)).
3.3. Mitochondrial Membrane Potential (Δ𝜓
𝑚
) Was Similar in
Parkin-Mutant and Control Fibroblasts. Given that Δ𝜓
𝑚
is a
central parameter of mitochondrial integrity, it was decided
to assess Δ𝜓
𝑚
in the fibroblast cell lines. The fibroblasts
were stained with the JC-1 potentiometric dye, and the green
and red fluorescent emissions of each cell population were
simultaneously measured by means of flow cytometry. Dif-
ferences inΔ𝜓
𝑚
were detected by dissimilarities in red : green
florescent emission ratios.The obtained red : green florescent
emission ratios of the patient-derived and control fibroblasts
are graphically illustrated in Figure 4. No significant differ-
ences in Δ𝜓
𝑚
were observed for parkin-mutant and control
fibroblasts (𝑝 = 0.1533).
3.4. Parkin-Mutant Fibroblasts Have Increased Cellular
Growth While Being More Susceptible to Mitochondrial
Insult. CyQUANT assays of cell growth were performed
to determine whether the overall state of cellular health
differed between parkin-mutant and control fibroblasts. As
illustrated in Figure 5, cell growth was significantly higher
in patient-derived fibroblasts than controls under basal
conditions (𝑝 = 0.0001). Fibroblast cell growth was also
assessed under conditions of cellular stress, as any differences
between patient-derived and control cells may not be readily
apparent under basal conditions. Here, the fibroblasts were
treated with CCCP to induce mitochondrial impairment
and subsequent parkin recruitment to the damaged
mitochondria. It was found that cell growth was similar
between patient and control fibroblasts even after CCCP
treatment (𝑝 = 0.0922). However, a comparison of the effect
of CCCP treatment within each fibroblast group (i.e., with
and without cellular stress) demonstrated that the growth
of patient-derived fibroblasts was significantly more blunted
by CCCP compared to the growth of control fibroblasts
(𝑝 = 0.0013). This is indicative of a heightened sensitivity to
CCCP of parkin-mutant fibroblasts in comparison to control
fibroblasts.
4. Discussion
A substantial body of evidence supports parkin’s involvement
in mitochondrial function. However, many of these studies
rely on artificially overexpressed or recombinantly tagged
parkin, which may introduce experimental artifacts [39,
40]. It is therefore pivotal to investigate parkin-associated
mitochondrial effects in appropriate cellular models where
parkin is expressed at endogenous levels. Patient-derived
dermal fibroblasts are particularly suitable for this, as their
use creates an ex vivo model system with the defined parkin
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Figure 2: Parameters of respiratory control in patient-derived and control fibroblasts. Boxplots depict grouped patients (P) and control (Ct)
values. (a) Basal mitochondrial OCR. (b) ATP-linked OCR. (c) OCR due to proton leak. (d) ATP coupling efficiency (percentage OCR due
to ATP synthesis). (e) Maximum OCR. (f) Percentage spare respiratory capacity. ∗𝑝 < 0.05; ∗∗𝑝 < 0.01; ∘, outlier; AU, arbitrary units; OCR,
oxygen consumption rate.
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Figure 3: Mitochondrial network analysis of patient-derived and control fibroblasts. Mitotracker Red and live-cell microscopy were used to
visualize the mitochondrial network. (a) Representative images of control fibroblasts (left) and patient fibroblasts (right). Scale bars = 20 𝜇m.
All images were assessed in regard to the degree of mitochondrial branching (form factor) and degree of mitochondrial elongation (aspect
ratio).The distribution of these parameters in grouped patient-derived (P) and grouped control (Ct) fibroblasts are represented on logarithmic
scale in boxplots, 𝑁 = 40. (b) Comparison of form factor, which was significantly lower in patient cells than in control cells (𝑝 = 0.0304).
(c) Comparison of aspect ratio, which was similar in patient and control cells (𝑝 = 0.1638). ∗𝑝 < 0.05; ∘, outlier; AU, arbitrary units;𝑁; cells
analyzed.
mutations and age-accumulated cellular damage of patients,
while being minimally invasive to donor individuals [24].
The present study functionally compared parkin-mutant
fibroblasts from South African PD patients with wild-type
control fibroblasts using a variety of assays of mitochondrial
health and function.
Surprisingly, it was found that the rate of mitochondrial
respiration was increased in parkin-mutant fibroblasts in
comparison to control fibroblasts. In particular, the patient
cells demonstrated markedly increased basal respiration,
elevated ATP-coupled respiration, and a higher maximal
respiratory rate. This is indicative of increased electron flow
through the respiratory chain, which is coupled to elevated
oxidative phosphorylation. The unanticipated increment in
mitochondrial respiration is in contrast to numerous studies
which have reported decreased respiratory activity in fibrob-
lasts from PD patients with parkin mutations. For example,
Mortiboys et al. [25] described significant impairment of
mitochondrial complex I activity in parkin-mutant fibrob-
lasts, which was linked to a loss ofΔ𝜓
𝑚
and decreased cellular
ATP content. Similarly, Pacelli et al. [27] reported that both
the basal and maximal respiratory rate were significantly
decreased in fibroblasts with parkinmutations. Further inves-
tigation of the specific respiratory complexes contributing to
the decline in respiratory flux demonstrated that activity of
complexes I, III, and IV was significantly reduced in patient
fibroblasts [27].
It is interesting to compare these results to a recent report
by Zanellati et al. [29], who used a similar experimental
approach to the present study to investigate mitochon-
drial respiration in parkin-mutant fibroblasts from four PD
patients. The authors likewise observed increased basal and
maximal respiration in patient cells; however, despite this
increment, they reported significantly lower ATP-coupled
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group (i.e., with and without cellular stress) demonstrated that the growth of patient-derived fibroblasts was significantly more suppressed
by CCCP than the growth of control fibroblasts (𝑝 = 0.0013). Fibroblasts from P1 were not available; results pertain to a comparison of P2
and P3 parkin-mutant fibroblast with the three controls. ∗∗𝑝 < 0.01; ∗∗∗𝑝 < 0.001; ∘, outlier; AU, arbitrary units.
respiration in mutants compared to controls. These findings
were associated with accordingly reduced cellular ATP levels
and impairment of Δ𝜓
𝑚
, suggesting that parkin-mutant
fibroblasts had uncoupled mitochondria. In contrast, the
present study revealed a significantly increased ATP-coupled
respiration in parkin-mutants, without any deficit in ATP-
coupling efficiency or impairment of Δ𝜓
𝑚
. The paradoxically
improved ATP-coupled respiration in the absence of parkin
seen in the present study likely reflects a compensatory
response in these parkin-mutant fibroblasts.
The present study found marked differences between the
mitochondrial network morphology of patient and control
fibroblasts. Whereas the degree of mitochondrial elongation
(aspect ratio) was comparable between patient-derived and
control fibroblasts, the amount of mitochondrial branching
(form factor) was significantly decreased in patients. This
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decrease in form factor is consistent with increased fragmen-
tation of the mitochondrial network [41]. We have previously
reported that mitochondrial networks were unaffected in P1,
P2, and P3 fibroblasts [28]. However, this follow-up study
used a larger control sample size and was therefore more
powered to detect differences in network parameters.
In contrast to the results obtained here, Mortiboys et
al. [25] found that fibroblasts with parkin mutations had a
marked increase in mitochondrial branching, as quantified
by the form factor, suggestive of increased mitochondrial
fusion in the absence of parkin. Two other studies indi-
cated that parkin-mutant and wild-type control fibroblasts
demonstrated comparable form factors under basal condi-
tions [26, 42]. However, both studies found that treatment
with mitochondrial stressors (paraquat and valinomycin,
resp.) decreased the form factor and induced mitochon-
drial network fragmentation in parkin-mutant and control
fibroblasts; these decreases were only statistically significant
in the fibroblasts with parkin mutations. These findings are
supported by the results of Pacelli et al. (2011), who observed
a noticeably more fragmented mitochondrial network in
parkin-mutant fibroblasts even under basal conditions; how-
ever, this differencewas not quantified in terms of form factor.
The results obtained here support these findings, but not the
contrasting findings of Mortiboys et al. [25].
Moreover, in the present study it was found that cell
growth was significantly higher in the parkin-mutant fibrob-
lasts under basal conditions, which is in contrast to the
published literature. For example, Mortiboys et al. [25]
reported that cell growth was similar in fibroblasts from
controls and patients with parkin mutations, whereas Pacelli
et al. [27] reported that parkin-mutant fibroblasts displayed
significantly lower growth than control fibroblasts. Both of
these studies reported cell growth under basal, unstressed
conditions. It is conceivable that the increased cell prolif-
eration in the absence of parkin observed in the present
study is a result of a metabolic shift in response to parkin
deficiency, which is known to promote cell proliferation in
various cancers with parkin mutations [43]. Furthermore,
while significant efforts were made to only use fibroblast cell
lines at low and comparable passage numbers, we cannot
exclude the possibility that some of the cell lines may have
undergone spontaneous transformation, which is known to
affect cell growth rates.
It is speculated that the significant increases in basal,
ATP-linked, and maximal respiratory rates of parkin-mutant
fibroblasts, as well as elevated growth rates of these cells, may
be due to a compensatory effect. In fact, several compensatory
responses to parkin deficiency have been described in the
literature. Pacelli et al. [27] reported that the defective ATP
production in parkin-mutant fibroblasts was compensated
by an upregulation of PGC1-𝛼 protein expression, suggestive
of a compensatory increase in mitochondrial biogenesis
[44]. However, the expressions of several PGC1-𝛼 target
genes directly involved in mitochondrial biogenesis (includ-
ing NRF1, TFAM, and COX II) were unchanged or even
decreased in patient-derived fibroblasts. Pacelli et al. pos-
tulated that an unknown posttranslational modification of
PGC1-𝛼modulated its function in parkin-mutant fibroblasts,
preventing a compensatory increase in mitochondrial bio-
genesis. It is interesting to speculate that the unique genetic
backgrounds of the fibroblasts in the current study may
allow for the PGC1-𝛼-mediated increase in mitochondrial
biogenesis. This deserves further study as it may, in part,
explain the conflicting results obtained here and by Pacelli et
al.
Other studies have also implied a compensatory increase
in mitochondrial biogenesis in parkin deficient fibroblasts.
Gru¨newald et al. [26] investigated citrate synthase activity as
an index of total mitochondrial mass and found that such
activity was significantly higher in parkin-mutant fibroblasts
than wild-type controls. Indeed, Gru¨newald et al. did not
observe any impairments of mitochondrial complexes I–IV
under basal conditions. Hence, increased citrate synthase
activity and elevatedmitochondrial biogenesis in generalmay
explain the milder phenotype of parkin-mutant fibroblasts
observed by Gru¨newald et al. While markers of mitochon-
drial biogenesis were not assessed in the present study,
increased biogenesismay underlie the compensatory increase
in mitochondrial respiration seen here. It is noted that a pos-
sible compensatory elevation of mitochondrial biogenesis in
the parkin-deficient fibroblasts would be paradoxical: parkin
is involved in the promotion of mitochondrial biogenesis;
hence, these processes are expected to be decreased in the
absence of parkin [45]. However, future investigation of the
exact nature andmechanism of the respiratory compensation
observed in parkin-mutant fibroblasts may reveal a more
complex and nuanced view of parkin and its interaction with
mitochondria.
These compensatory responses are likely dependent on
cell- and tissue-specific metabolic capacity and adaptations
[46]. Hence, the observations made here on patient-derived
fibroblasts should not be extrapolated to possible effects in
a neuronal environment, as neurons may be more restricted
in their compensatory repertoire than dermal fibroblasts.
Furthermore, many of the described functional roles of
parkin are cell-type specific which will result in different
functional effects of parkin deficiency in fibroblasts and
neurons [47]. Ideally, the observations made in this study
should be verified in a neuronal model, such as induced
pluripotent stem cell- (iPSC-) derived neurons with parkin
mutations.
We recognize several limitations of this study. The find-
ings are limited by the small sample size of three patient-
derived fibroblasts cell lines, of which only two were available
for Δ𝜓
𝑚
and cell growth assays. Furthermore, two of the
patients recruited for this study were siblings. The small
sample size reflects the scarcity of parkin-mutant fibroblast
models, which is also apparent in the small sample sizes
(two to six) of previous studies on parkin-mutant fibroblasts
[25–29]. It is recommended that the findings reported here
be verified in a larger group of patients and controls. We
also recommend stringent quality control measures when
performing functional assays in fibroblasts, considering that
cell growth, respiration, and oxidative stress can be greatly
influenced by cellular senescence, spontaneous transforma-
tion, or undetected mycobacterial infections.
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The functional effects of parkin deficiency observed in
this exploratory study were assessed in fibroblasts cultured
under basal, unstressed conditions. Given parkin’s important
role in the cellular stress response, mitochondrial impair-
ments in Δ𝜓
𝑚
in parkin-mutant fibroblasts may only be read-
ily observable under highly oxidative conditions, where the
cells are more reliant on mitochondria for ATP production.
Future studies should aim to compare the results obtained
here to fibroblasts cultured under more stressed or oxidative
conditions, particularly in regard to the mitochondrial respi-
ration and Δ𝜓
𝑚
analyses.
In conclusion, our results do not support the findings of
impairment of mitochondrial respiration in parkin-mutant
fibroblasts, while concurring with previous reports of altered
mitochondrial dynamics in these cells. These preliminary
findings suggest a compensatory response in the patient
fibroblasts used in this study. Future studies should aim at
investigating the molecular mechanism of the mitochondrial
compensation in the absence of parkin; proteomic analyses
of parkin-mutant fibroblasts may be particularly suitable to
identify dysregulated biological processes. Insights derived
from these studies may have important implications for
therapeutic strategies aimed at preserving mitochondrial
function in PD patients.
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